First Drug Designed for Pediatric Tics Halves Relapse Risk in Phase 3 Tourette Syndrome Trial

For the estimated one percent of school-aged children living with Tourette syndrome, managing the condition's hallmark motor and vocal tics has long required a difficult compromise. The medications currently approved to suppress severe tics are repurposed antipsychotics, originally designed to treat schizophrenia. While effective, they carry a heavy burden of side effects, forcing many families to abandon treatment altogether. Now, a landmark Phase 3 clinical trial published in JAMA Neurology offers a highly anticipated alternative. Ecopipam, a novel investigational drug specifically designed for Tourette syndrome, has been shown to cut the risk of tic relapse in half for pediatric patients. The findings represent the most significant pharmacological breakthrough for the neurodevelopmental disorder in over a decade, paving the way for what could soon become the first non-antipsychotic treatment approved by the US Food and Drug Administration.[1][2]

Tourette syndrome is a chronic condition that typically emerges before age ten, occurring more frequently in boys. It is characterized by involuntary, repetitive movements and vocalizations—such as excessive blinking, facial grimacing, shrugging, or grunting—that can cause significant physical discomfort and social distress. When behavioral interventions like Comprehensive Behavioral Intervention for Tics are insufficient, pediatricians turn to pharmacotherapy. For years, the only FDA-approved options have been haloperidol, pimozide, and aripiprazole. These drugs operate by broadly blocking dopamine D2 receptors in the brain to dampen the excessive neuronal activity that triggers tics. However, this D2 blockade frequently leads to severe metabolic changes, rapid weight gain, extreme fatigue, and in some cases, drug-induced movement disorders known as tardive dyskinesia.[6][7]

Ecopipam, originally developed by Emalex Biosciences and recently acquired by Teva Pharmaceuticals, takes a fundamentally different approach to the brain's dopamine system. Instead of targeting the D2 receptor, ecopipam is a first-in-class selective antagonist for the dopamine D1 receptor. The basal ganglia, the brain region responsible for motor control, relies on a delicate balance of signals mediated by both D1 and D2 receptors. Emerging neurological research suggests that hypersensitivity in the D1 receptor pathway may actually be the primary driver of the uncontrolled movements seen in Tourette syndrome. By selectively blocking D1 receptors, ecopipam aims to quiet the specific neurological circuits responsible for tics without disrupting the broader dopamine functions that govern metabolism and voluntary movement.[3][4]

To test this targeted mechanism, researchers launched a massive Phase 3 clinical trial across 77 sites in 12 countries, enrolling 216 participants aged six and older. The study, led by Dr. Donald Gilbert, a pediatric movement disorders specialist at Cincinnati Children's Hospital Medical Center, utilized a randomized-withdrawal design to rigorously test the drug's long-term efficacy. During the initial 12-week open-label phase, all participants received ecopipam, with doses carefully titrated based on body weight to a target of 1.8 milligrams per kilogram per day. This phase allowed researchers to identify which patients actually responded to the medication, defined as achieving at least a 25 percent improvement on the Yale Global Tic Severity Scale.[1][6]

Following the open-label period, the trial moved into its critical double-blind withdrawal phase. The 104 participants who had successfully responded to ecopipam—90 of whom were children and adolescents—were randomly divided into two groups. One cohort continued receiving their established dose of ecopipam, while the other was slowly tapered off the active drug and switched to a placebo. For the next 12 weeks, researchers monitored the patients to see how long it would take for their severe tics to return. By focusing on relapse prevention in known responders, the trial design specifically mirrored the real-world clinical challenge of maintaining long-term symptom control in pediatric patients.[2][5]

The results of the withdrawal phase were striking. Pediatric patients who continued taking ecopipam experienced a 53 percent lower risk of relapse compared to those who were switched to the placebo. The data, which achieved high statistical significance with a p-value of 0.008, demonstrated that the D1 receptor antagonist could durably suppress tics over an extended period. In fact, the median time to relapse was not even reached for the group taking the active therapy during the 12-week double-blind window, indicating a sustained therapeutic effect. For pediatric neurologists, the data confirms that ecopipam is not just a short-term fix, but a viable maintenance therapy for chronic tic management.[1][4]

Just as important as the drug's efficacy was its safety profile, which stood in stark contrast to the traditional antipsychotics currently dominating the market. Throughout the 24-week study period, researchers observed no clinically meaningful changes in the patients' weight or metabolic parameters. Furthermore, ecopipam did not induce the secondary movement disorders that often plague patients on D2 antagonists. Dr. Gilbert noted that the combination of significant tic reduction without weight gain or metabolic disruption is an exciting prospect that could make pediatricians far more comfortable prescribing pharmacological treatments, and families much more willing to maintain them.[5][6]

While ecopipam avoided the severe metabolic pitfalls of older drugs, it was not entirely without side effects. The most common adverse events reported during the trial were primarily related to the central nervous system. Approximately 11 percent of participants experienced somnolence or sleepiness, while nearly 10 percent reported anxiety or headaches. Insomnia and general fatigue were also noted in smaller percentages of the cohort. However, researchers classified these side effects as generally mild to moderate, and they were consistent with the safety data observed in earlier, smaller-scale Phase 2 trials of the drug. Crucially, the discontinuation rate due to these side effects was remarkably low.[2][4]

Armed with the successful Phase 3 data, Teva Pharmaceuticals moved swiftly to bring the drug to market. On June 18, 2026, the company announced that it had officially submitted a New Drug Application to the FDA for ecopipam as a treatment for pediatric Tourette syndrome. Because the FDA had previously granted ecopipam both Orphan Drug and Fast Track designations—regulatory statuses designed to expedite the development of drugs for rare diseases with significant unmet needs—the review process is expected to move quickly. If approved, ecopipam will become the first new medication authorized for Tourette syndrome in over ten years.[3][7]

Despite the overwhelming success in the pediatric cohort, the trial did leave some questions unanswered, particularly regarding adult patients. The study included a small cohort of 14 adult participants with Tourette syndrome. While the adult data trended in the same positive direction as the pediatric results, the sample size was simply too small to achieve statistical significance. Consequently, Teva's initial FDA application is focused exclusively on the pediatric population. Further research with larger adult cohorts will be necessary to determine if the D1 receptor antagonist can provide the same durable relapse prevention for older patients who continue to struggle with severe tics into adulthood.[1][5]

Clinical researchers are also emphasizing the need for longer-term safety data. While the 24-week trial provided a robust window into ecopipam's efficacy and tolerability, Tourette syndrome is a chronic condition that often requires years of continuous management. Post-market surveillance and ongoing extension studies will be critical to ensure that the drug's safety profile holds up over years of daily use, and to confirm that patients do not develop a tolerance to the D1 blockade over time. Additionally, future studies may explore how ecopipam performs in head-to-head comparisons against behavioral therapies or existing alpha-2 agonists.[4][6]

For the Tourette syndrome community, the imminent arrival of a targeted, non-antipsychotic medication represents a profound shift in the treatment landscape. For decades, the therapeutic pipeline for tic disorders has been largely stagnant, leaving families to choose between the social stigma of uncontrolled vocal and motor tics and the physical toll of heavy psychiatric medications. By proving that the D1 receptor is a viable and highly effective target, the ecopipam trials have not only validated a new biological mechanism but have also offered a tangible path forward for thousands of children seeking relief without compromise.[2][3]